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Abstract 27 
The number of onsite clinical microbiology laboratories in hospitals is decreasing, likely related 28 
to the business model for laboratory consolidation and labor shortages, and this impacts a 29 
variety of clinical practices including banking isolates for clinical or epidemiologic purposes. To 30 
determine the impact of these trends, infectious disease (ID) physicians were surveyed 31 
regarding their perceptions of offsite services.  Clinical microbiology practices for retention of 32 
clinical isolates for future use were also determined.  Surveys were sent to members of the 33 
Infectious Diseases Society of America’s (IDSA) Emerging Infections Network (EIN).  The EIN is 34 
a sentinel network of ID physicians who care for adult and/or pediatric patients in North America 35 
and who are members of IDSA.  The response rate was 763 (45%) of 1,680 potential 36 
respondents.  Five hundred forty (81%) respondents reported interacting with the clinical 37 
microbiology laboratory.  Eighty-six percent of respondents thought an onsite laboratory very 38 
important for timely diagnostic reporting and ongoing communication with the clinical 39 
microbiologist.  Thirty-five percent practiced in institutions where the core microbiology 40 
laboratory has been moved offsite, and an additional 7% (N=38) reported that movement of 41 
core laboratory functions offsite was being considered.  The respondents reported that only 24% 42 
of laboratories banked all isolates with the majority saving isolates for less than 30 days.  Based 43 
on these results, the trend towards centralized core laboratories negatively impacts the practice 44 
of ID physicians, potentially delays effective implementation of prompt and targeted care for 45 
patients with serious infections, and similarly adversely impacts infection control epidemiologic 46 
investigations. 47 
  48 
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Introduction 49 
During the past three decades, clinical laboratories have faced a new business model driven by 50 
a reimbursement system that encourages economies of scale and large volume testing (1,2).  At 51 
the same time there have been the additional issues of increasing labor force shortages of 52 
experienced microbiologists and the emergence of new complex and costly diagnostic 53 
technologies (2). In response to these economic realities, a number of clinical microbiology 54 
laboratories have either moved to locations remote from the main hospital facility in order to 55 
expand laboratory capacity whereas others have consolidated laboratory facilities in multi-56 
hospital systems.(3-6) Yet while these consolidations can offer economies of scale and the 57 
more ready introduction of sophisticated expensive technologies, these remote site laboratories 58 
present challenges both for quality of services and communication.(6,7).  The partnership of the 59 
clinical microbiologist and the infectious disease physician can result in better use of laboratory 60 
services and improvement in patient care quality; distance can strain, if not completely 61 
eliminate, these benefits.(8,9) Beyond this, as off-site laboratories lose a primary relationship 62 
with a given institution, and may in fact become separate for-profit entities, the associated costs 63 
associated with retaining clinical isolates for future epidemiologic may now require formal 64 
budgetary justification.(9) 65 
 66 
To determine the impact of these trends, infectious disease physicians were surveyed regarding 67 
their experiences with offsite services.  This survey was not designed to determine the impact of 68 
offsite laboratory services on the quality of patient care, but rather to describe the impact on 69 
infectious diseases physicians.  The move away from hospital-based laboratories also may 70 
have decreased the number of institutions which save isolates, which allows for repeat or 71 
additional testing for a variety of needs, including infection control investigations, further 72 
investigation for public health purposes, and for quality control purposes. We also were 73 
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interested in whether clinical isolates were retained for future use and policies regarding this 74 
practice. 75 
 76 
Methods 77 
We sent a twelve-question primary survey and a 5 question sub-survey on isolate retention to 78 
physician members of the Infectious Diseases Society of America’s (IDSA) Emerging Infections 79 
Network (EIN). The EIN is a sentinel network of infectious diseases (ID) physicians who care for 80 
adult and/or pediatric patients in North America and who are members of IDSA.(10) The survey 81 
was collaboratively developed by the study authors and reviewed by ID physicians currently in 82 
clinical practice for content validity and pilot testing. On May 22, 2018, all 1,830 members of the 83 
EIN received the confidential survey by email link or by facsimile. Non-responders received two 84 
reminders, and physicians who had joined the EIN but had not yet responded to any surveys 85 
were excluded (N=150), resulting in a denominator of 1,680 physician members. An opt-out 86 
option was provided for those physicians who did not interact with the clinical microbiology 87 
laboratory in their primary institutions. The survey remained open until June 14, 2018, and is 88 
provided as an appendix. 89 
 90 
The physicians were asked to indicate if a list of clinical microbiology laboratory services were 91 
performed onsite in their primary institutions as well as their satisfaction with this laboratory’s 92 
services, whether any core microbiology functions had been moved offsite, and if so, a series of 93 
questions about the offsite location. Also, physicians were queried as to whether the 94 
microbiology laboratory banked any isolates, and if so, were asked to open a second link to 95 
respond to a brief sub-survey on isolate retention. In this sub-survey, questions asked included 96 
which isolates were saved and for how long, whether these saved isolates had been used, and 97 
any impact on clinical practice. Practice information for each respondent, including employment, 98 
geographic location and years of practice, was imported from an EIN database. Not all 99 
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respondents answered all questions, so totals for individual questions vary. Chi-square and 100 
Fisher’s exact tests were used for univariate analyses. Data were analyzed using SAS software 101 
version 9.4 (SAS institute, Cary, NC). 102 
 103 
Results  104 
The overall response rate to the survey was 763 (45%) of 1,680 potential respondents, with 441 105 
(26%) respondents answering only the Clinical Microbiology Laboratory Services survey, 95 106 
(6%) respondents answering only the Isolate Retention (banking) sub-survey and 227 (13.5%) 107 
responding to both. All regions of the U.S. were well represented (see Table 1). The years of 108 
experience since infectious disease fellowship ranged from less than 5 years to more than 25 109 
years with the largest number of respondents (29%) having more than 25 years of experience.  110 
A university/medical school work setting accounted for 47% of respondents, and 48% (364/763) 111 
were associated with community and non-university teaching hospitals.  A sizable number of 112 
respondents (N=190, 35%) practiced in institutions where the core microbiology laboratory has 113 
been moved off site, and an additional 7% (N=38) reported that movement of core laboratory 114 
functions offsite was being considered. 115 
 116 
Eighty-six percent of respondents thought an onsite laboratory to be very important for timely 117 
diagnostic reporting and ongoing communication with the clinical microbiologist.  Slightly fewer 118 
felt that onsite laboratories were important for education/teaching (75% very important, 20% 119 
slightly or moderately important). Respondents most often reported that their primary 120 
microbiology laboratories always met their expectations with communication with laboratory 121 
management/director (64%) and with microbiology laboratory bench personnel (59%). The 122 
overall quality and accuracy of microbiology laboratory results always met expectations for 50% 123 
of respondents, followed by electronic reporting of micro results (48%) and handling of 124 
mycobacteriology specimens and issues (46%). Turnaround time for microbiology laboratory 125 
 o
n
 M
arch 25, 2020 at UNIV O
F M
ASS M
ED SCH
http://jcm.asm.org/
D
ow
nloaded from
 
 Page 6 
results met respondents’ expectations least often, with 35% saying their expectations were 126 
always met and 63% indicating that their expectations were either mostly or sometimes met.   127 
 128 
In the area of post-testing physician needs, the respondents reported that only 24% of 129 
laboratories banked all isolates with the majority saving isolates for less than 30 days.  130 
However, 72% of the laboratories would save isolates on request.  Of the respondents, over 131 
50% had made use of banked isolates in the last year with 160 (51%) of 321 doing so for direct 132 
clinical care and 168 (54%) for epidemiological investigations.  Additionally, 166 (52%) 133 
respondents indicated there had been a time in the past year when an isolate was needed but 134 
was not available because of the laboratory’s retention policy.   135 
 136 
Five hundred forty (81%) respondents reported interacting with the clinical microbiology 137 
laboratory, and the laboratory services available onsite at their institutions are summarized in 138 
table 2. Those services include: 74% have after hours Gram stain interpretation; 88% have on 139 
site blood cultures, but only 61% have blood culture rapid identification methods; 78% have 140 
respiratory virus panel testing but only 61% have Legionella urinary antigen testing; 84% have 141 
onsite Clostridioides difficile testing; 50% have adopted the MALDI ToF technology for bacterial 142 
identification. 143 
 144 
Two hundred nine respondents (all of those whose institutions had moved functions offsite plus 145 
19 of those whose institutions were considering such a move) then answered six questions 146 
about their offsite microbiology laboratory. Of the respondents who had experience with an 147 
offsite laboratory, 74% perceived that the offsite laboratory has a negative impact on overall 148 
infectious diseases patient care and outcomes (either major or minor) with the primary negative 149 
effects relating to turnaround time and communication with the laboratory.  Of the respondents 150 
who had experience with an offsite laboratory, 57% said that the transport time to the offsite 151 
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location is greater than 30 minutes. Ten percent of these respondents reported a positive impact 152 
(either minor or major) most often related to overall availability of lab services and technologies. 153 
In addition, 47% felt that an offsite laboratory adversely impacted infectious disease medical 154 
education. Only 65% felt that infectious disease physicians have any input into microbiology 155 
laboratory policies that affect their practice. 156 
 157 
Discussion 158 
While the model of test delivery is changing, the science of clinical microbiology is becoming 159 
more complex.  The need for a strong partnership between the infectious disease physician and 160 
the clinical microbiology laboratory has always been important, but the need appears to 161 
becoming even greater in recent years given the development of new methods, instruments, 162 
automation, and the desire for shorter turnaround times.(8) Moreover, optimal utilization of these 163 
newer technologies such as MALDI-ToF, multiplex PCR systems, next generation sequencing, 164 
and rapid antimicrobial resistance determination will be dependent on consultation between the 165 
infectious disease physician and the laboratory director. 166 
 167 
Based on the results of this survey, the trend towards centralized core laboratories has 168 
impacted the practice of infectious disease physicians and, in their perspective, not in a positive 169 
way.  A marked majority of the survey respondents indicated that they felt that onsite testing is 170 
important for timely diagnostic reporting and ongoing communication with clinical microbiology. 171 
However, 35% of the respondents reported that their clinical microbiology laboratory is now 172 
located offsite, with more than half of these laboratories more than 30 minutes from their 173 
institution which would impede any possibility of a brief in-person meeting or the possibility of 174 
the infectious disease physician quickly visiting the laboratory.  This points to the need for 175 
laboratory directors to consider alternate means to connect with the infectious disease physician 176 
community to build the necessary communication channels. 177 
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 178 
Importantly, many respondents to this survey are not satisfied with the services provided by 179 
their clinical microbiology laboratory given that on only 35 to 64% of six measures were the 180 
laboratories always meeting their expectations.  This lack of satisfaction is supported by the 181 
reported limitations in clinical microbiology services at the respondents’ hospitals as only 74% 182 
had known onsite Gram stain interpretation after hours, and many clinical microbiology 183 
laboratories are not keeping up with new technology with only 61% of the facilities providing 184 
rapid blood culture identification methods and only 50% having adopted MALDI-ToF technology.  185 
As another indicator of service, infectious disease physician respondents were asked about the 186 
retention of isolates by the clinical microbiology laboratory.  Seventy-two percent responded that 187 
they could have an isolate saved if requested yet over 50% had a need for a retained isolate in 188 
the past year. 189 
 190 
A significant impact of an offsite clinical microbiology was to medical education as noted by 47% 191 
of the respondents.  However, the respondents also felt that they did not have much impact on 192 
the operations of the laboratory, and the lack of communication impedes the ability of 193 
microbiologists and clinicians to work together in optimizing the selection and utilization of the 194 
new technological advances in clinical microbiology such as rapid blood culture identification 195 
and MALDI-Tof systems.(5)   196 
 197 
From the available data in the literature, consideration of costs (10) is a major factor in the 198 
decision to send specimens to an outside laboratory, but administrators do not quantify or know 199 
the cost of keeping patient in hospital longer or the cost of additional tests or empiric treatment 200 
until culture or other results return.(11) In addition, despite the recommendations that the clinical 201 
microbiologist collaborate in antibiotic stewardship programs,(10) when the laboratory is offsite 202 
there is not sufficient opportunity for interaction between the infectious disease physician and 203 
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the clinical microbiology laboratory to allow this. It is possible that the use of video conferencing 204 
and tele-microbiology may compensate for direct interactions, but such services do not appear 205 
to be routinely available at this time. Beyond all of these issues, ongoing efforts to improve the 206 
quality of patient care, decrease length of stay, and meet benchmarks such as for sepsis 207 
protocols (e.g., treating patients at the earliest possible time) are all driving the need for near 208 
patient diagnostics, and offsite laboratories may have difficulty supporting these needs (10).  209 
 210 
Another concern arising from the move to centralized non-institution based laboratories is the 211 
ability of the microbiology laboratory to assist in infection control/public health activities,( 6, 9, 212 
12, 13, 14 ) and the finding that only a minority of laboratories are now retaining isolates. There 213 
has been increasing concern about healthcare associated infections, cross transmission of 214 
multidrug resistant organisms, as well as point source outbreaks within hospitals and the 215 
general community. However, the ability to determine actual cross transmission events is 216 
dependent on the ability to type or sequence pathogens; and multiple studies have shown that 217 
for epidemiologic purposes typing needs to be performed using molecular typing methodologies 218 
such as pulse field gel electrophoresis or whole genome sequencing. (15-17) Such additional 219 
characterization can only be done if there has been retention of isolates potentially linked to 220 
cross transmission events or presumed outbreaks, and if measures are not in place to retain 221 
such isolates, the public health benefit of identifying and controlling outbreaks is lost.  While the 222 
ability to retain isolates is independent of location of the laboratory, retention of isolates serves 223 
as an indicator of meeting an essential need of the physician.   224 
 225 
Our findings are subject to a number of limitations. To maximize the response rate, the survey 226 
was designed to be relatively straightforward for respondents to complete. Consequently, more 227 
detailed analyses of the use of newer technologies or the breakdown of services available on-228 
and off-site were not possible.  While the EIN represents about 18% of IDSA physician 229 
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members and about 20% of subspecialty boarded physicians, our members are not randomly 230 
selected. Since our members “self-select” to join the EIN, we do not make any claims that our 231 
members are representative of the broad population of infectious diseases physicians. This was 232 
a descriptive survey which reflects the perceptions and opinions of the responding infectious 233 
diseases physicians and should be validated with additional data about specific interactions 234 
between infectious diseases physicians and laboratory personnel.  Moreover, the perceptions 235 
and opinions of laboratory directors were not incorporated into the survey. 236 
 237 
Conclusions 238 
It has been recommended that “maintaining high-quality clinical microbiology laboratories on the 239 
site of the institution that they serve is the current best approach for managing today’s problems 240 
of emerging infectious diseases and antimicrobial agent resistance by providing good patient 241 
care outcomes that actually save money.”(9) Unfortunately, the findings of this survey indicate 242 
that the shift from institution-based to core laboratory facilities is having a negative impact on 243 
infectious disease physicians and their relationship with the clinical microbiology laboratory.  As 244 
yet unanswered is the impact of this trend on the care of the patient, the cost of medical care for 245 
those with serious infections, and the public health issues of antimicrobial resistance and 246 
emerging infectious diseases. Going forward it will be important for institutions to develop key 247 
performance indicators related to laboratory services so that the relative utility of on-site and off-248 
site laboratories in all of these can be better defined. 249 
 250 
  251 
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TABLES 319 
 320 
Table 1. Practice characteristics of 763 respondents  321 
Infectious diseases practice Adult 
Pediatric 
672 (75) 
191 (25) 
U.S. Census Bureau division New England 
Mid Atlantic 
East North Central 
West North Central 
South Atlantic 
East South Central 
West South Central 
Mountain 
Pacific 
Puerto Rico 
Canada 
52 (7) 
114 (15) 
106 (14) 
79 (10) 
134 (18) 
37 (5) 
52 (7) 
40 (5) 
141 (18) 
1 (0.1) 
7 (1) 
Years’ experience since ID fellowship  < 5 years 
5-14 
15-24 
≥25 years 
173 (23) 
225 (29) 
145 (19) 
220 (29) 
Employment Hospital/clinic 
Private/group practice 
University/medical school 
VA and military 
State government 
224 (32) 
167 (22) 
305 (40) 
43 (6) 
4 (0.5) 
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 Primary hospital type Community 
Non-university teaching 
University 
VA hospital or DOD 
City/country 
163 (22) 
201 (26) 
323 (42) 
48 (6) 
28 (4) 
Practice settings where laboratory is 
offsite 
Yes 
No 
Maybe  
190 (35) 
312 (58) 
38 (7) 
DOD- U.S. Department of Defense 322 
 323 
  324 
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Table 2. Which of the following lab services are performed ONSITE in your primary  325 
institution? [N=540] 
Available 
onsite 
 
Offsite only 
Not sure / 
Not 
answered 
Gram stain interpretation Monday through Friday 
8am-3pm 
491 (91%) 25 (5%) 24 (4%) 
Blood culture bottle processing 476 (88%) 44 (8%) 20 (4%) 
C. difficile testing (e.g. GDH, NAAT) 453 (84%) 50 (9%) 37 (7%) 
Identification and susceptibility testing of sterile site 
isolates 
429 (80%) 60 (11%) 51 (9%) 
Respiratory virus panel testing (e.g. RSV, 
influenza) 
421 (78%) 63 (12%) 56 (10%) 
Blood smears for infection (e.g. malaria, 
Anaplasma, Ehrlichia) 
403 (75%) 64 (12%) 73 (13%) 
Gram stain interpretation Monday through Friday 
11pm-6am 
399 (74%) 37 (7%) 104 (19%) 
AFB stains and culture 338 (63%) 105 (19%) 97 (18%) 
GI pathogens panel (e.g. Salmonella, norovirus) 335 (62%) 94 (17%) 111 (21%) 
Blood culture rapid ID (e.g. BioFire, Verigene) 331 (61%) 90 (17%) 119 (22%) 
Legionella urinary antigen 327 (61%) 97 (18%) 116 (21%) 
MALDI-TOF identification system for bacteriology 270 (50%) 121 (22%) 149 (28%) 
Nucleic acid amplification test (NAAT) for M. 
tuberculosis 
231 (43%) 158 (29%) 151 (28%) 
 326 
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